Prescription Drugs

CLINICAL PHARMACOLOGY In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the release of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell. Another activity demonstrated in vitro is the capacity of cromolyn sodium to inhibit the degranulation of non-sensitized rat mast cells by phospholipase A and the subsequent release of chemical mediators. Another study showed that cromolyn sodium did not inhibit the enzymatic activity of released phospholipase A on its specific substrate. Cromolyn sodium has no intrinsic vasoconstrictor, antihistamine, or anti-inflammatory activity. Cromolyn sodium is poorly absorbed. When multiple doses of cromolyn sodium ophthalmic solution are instilled into normal rabbit eyes, less than 0.07% of the administered dose of cromolyn sodium is absorbed into the systemic circulation (presumably by way of the eye, nasal passages, buccal cavity, and gastrointestinal tract). Trace amounts (less than 0.01%) of the cromolyn sodium dose penetrate into the aqueous humor and clearance from this chamber is virtually complete within 24 hours after treatment is stopped. In normal volunteers, analysis of drug excretion indicates that approximately 0.03% of cromolyn sodium is absorbed following administration to the eye.

Optimcrom (cromolyn sodium) Ophthalmic Solution, USP 4% Sterile DESCRIPTION OPTICROM (cromolyn sodium ophthalmic solution, USP) 4% is a clear, colorless, sterile solution intended for topical ophthalmic use. Cromolyn sodium is represented by the following structural formula: C23H14Na2O11....................Mol. Wt 512.34 Chemical Name: disodium 5-5' - [(2-hydroxytrimethylene) dioxy] bis [4-oxo-4H-1 -benzopyran-2-carboxylate]. Pharmacologic Category! Mast cell stabilizer Each mL contains: Active: Cromolyn sodium 40 mg (4%); Preservative: Benzalkonium chloride 0.01%; Inactives: Edetate disodium 0.1% and purified water. It has a pH of 4.0 to 7.0.

INDICATIONS OPTICROM (cromolyn sodium ophthalmic solution) is indicated in the treatment of vernal kerato conjunctivitis, vernal conjunctivitis, and vernal keratitis. DOSAGE AND ADMINISTRATION The dose is 1-2 drops in each eye 4-6 times a day at regular intervals. One drop contains approximately 1.6 mg cromolyn sodium. Patients should be advised that the effect of OPTICROM (cromolyn sodium ophthalmic solution) therapy is dependent upon its administration at regular intervals, as directed. Symptomatic response to therapy (decreased itching, tearing, redness, and discharge) is usually evident within a few days, but longer treatment for up to six weeks is sometimes required. Once symptomatic improvement has been established, therapy should be continued for as long as needed to sustain improvement. If required, corticosteroids may be used concomitantly with OPTICROM. HOW SUPPLIED OPTICROM (cromolyn sodium ophthalmic solution, USP) 4% is supplied as 10 mL of solution in an opaque polyethylene eye drop bottle. 10 mL NDC 0023-6422-10 Store at Controlled Room Temperature 20-25°C (68-77°F). Protect from light - store in original carton. Keep tightly closed and out of the reach of children. Allergan Inc., Irvine, CA 92612 U.S.A. Revised October 2000. FDA rev date: 4/12/2002

OVERDOSE No information provided. CONTRAINDICATIONS OPTICROM (cromolyn sodium ophthalmic solution) is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium or to any of the other ingredients.

SIDE EFFECTS The most frequently reported adverse reaction attributed to the use of OPTICROM (cromolyn sodium ophthalmic solution, USP) 4%, on the basis of reoccurrence following readministration, is transient ocular stinging or burning upon instillation. The following adverse reactions have been reported as infrequent events. It is unclear whether they are attributed to the drug: Conjunctival injection; watery eyes; itchy eyes; dryness around the eye; puffy eyes; eye irritation; and styes. Immediate hypersensitivity reactions have been reported rarely and include dyspnea, edema, and rash. DRUG INTERACTIONS No information provided.

WARNINGS No information provided. PRECAUTIONS General Patients may experience a transient stinging or burning sensation following application of OPTICROM (cromolyn sodium ophthalmic solution, USP) 4%. The recommended frequency of administration should not be exceeded (see DOSAGE AND ADMINISTRATION). Information for Patients Patients should be advised to follow the patient instructions listed on the Information for Patients sheet. Users of contact lenses should refrain from wearing lenses while exhibiting the signs and symptoms of vernal kerato conjunctivitis, vernal conjunctivitis, or vernal keratitis. Do not wear contact lenses during treatment with OPTICROM (cromolyn sodium ophthalmic solution) . Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long term studies of cromolyn sodium in mice (12 months intraperitoneal administration at doses up to 150 mg/kg three days per week), hamsters (intraperitoneal administration at doses up to 52.6 mg/kg three days per week for 15 weeks followed by 17.5 mg/kg three days per week for 37 weeks), and rats (18 months subcutaneous administration at doses up to 75 mg/kg six days per week) showed no neoplastic effects. The average daily maximum dose levels administered in these studies were 192.9 mg/m2 for mice, 47.2 mg/m2 for hamsters and 385.8 mg/m2 for rats. These doses correspond to approximately 6.8, 1.7, and 14 times the maximum daily human dose of 28 mg/m2. Cromolyn sodium showed no mutagenic potential in the Ames Salmonella/microsome plate assays, mitotic gene conversion in Saccharomyces cerevisiae and in an in vitro cytogenetic study in human peripheral lymphocytes. No evidence of impaired fertility was shown in laboratory reproduction studies conducted subcutaneously in rats at the highest doses tested, 175 mg/kg/day (1050 mg/m2) in males and 100 mg/kg/day (600 mg/m2) in females. These doses are approximately 37 and 21 times the maximum daily human dose, respectively, based on mg/m2. Pregnancy Teratogenic Effects: Pregnancy Category B: Reproduction studies with cromolyn sodium administered subcutaneously to pregnant mice and rats at maximum daily doses of 540 mg/kg (1620 mg/m2) and 164 mg/kg (984 mg/m2), respectively, and intravenously to rabbits at a maximum daily dose of 485 mg/kg (5820 mg/m2) produced no evidence of fetal malformation. These doses represent approximately 57,35, and 205 times the maximum daily human dose, respectively, on a mg/m2 basis. Adverse fetal effects (increased resorption and decreased fetal weight) were noted only at the very high parenteral doses that produced maternal toxicity. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when OPTICROM (cromolyn sodium ophthalmic solution) is administered to a nursing woman. Pediatric use Safety and effectiveness in children below the age of 4 years have not been established. Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.